Document Detail


Correlation between the growth-inhibitory effect of TGF-beta 1 and phenotypic characteristics in a panel of B-cell lines.
MedLine Citation:
PMID:  8393838     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Human B-cell lines established from Burkitt lymphoma (BL) and normal B cells immortalized in vitro by EBV (LCLs) differ in phenotype. While the BL correspond to resting B cells, the LCLs resemble activated B cells. When BLs which have the EBV genome are carried in vitro, they acquire some of the features of LCLs, such as expression of B-cell activation markers and the tendency to form aggregates. Comparison of several B-cell lines for sensitivity to TGF-beta showed that the growth of BLs (with few exceptions), but not of the LCLs, was inhibited. The results suggested that the sensitivity to TGF-beta correlates with the cellular phenotype. In the present work, this assumption is even more critically substantiated by studying 2 sublines of an EBV-genome carrying BL line, Mutu, which were selected for single cells and aggregates. The former (with resting phenotype) was inhibited, while the subline of aggregated cells, which also expressed B-cell activation markers, was not inhibited. Somatic-cell hybrids between BLs, LCLs and non-B cells provided lines with phenotypic differences. Results with a panel of such hybrid lines also showed that those which express the activated B-cell phenotype are not inhibited by TGF-beta. Differences in the levels of expression of activation markers did not influence the response to TGF-beta.
Authors:
A Altiok; B Ehlin-Henriksson; E Klein
Related Documents :
8702548 - Anti-igm-mediated regulation of c-myc and its possible relationship to apoptosis.
6300308 - Relationship between epstein-barr virus nuclear antigen and dna genome number in superi...
8882968 - Adult t-cell leukemia (atl) with an unusual immunophenotype and a high cellular prolife...
10729998 - Successful treatment of disseminated nasal nk/t-cell lymphoma using double autologous p...
18157938 - Dock2 participates in bone marrow lympho-hematopoiesis.
8103248 - Molecular mimicry between hiv-1 and antigen receptor molecules: a clue to the pathogene...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  55     ISSN:  0020-7136     ISO Abbreviation:  Int. J. Cancer     Publication Date:  1993 Aug 
Date Detail:
Created Date:  1993-09-03     Completed Date:  1993-09-03     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  137-40     Citation Subset:  IM    
Affiliation:
Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
B-Lymphocytes / cytology,  drug effects*
Burkitt Lymphoma / pathology
Cell Division / drug effects
Cell Line
Cell Line, Transformed
Herpesvirus 4, Human
Humans
Hybrid Cells
Immunophenotyping
Lymphocyte Activation / physiology
Transforming Growth Factor beta / pharmacology*
Grant Support
ID/Acronym/Agency:
2RO1 CA25250-13/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Transforming Growth Factor beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increased production of TGF-beta and Il-6 by aged spleen cells.
Next Document:  Mouse mammary-tumor virus activates Fgf-3/Int-2 less frequently in tumors from virgin than from paro...